Understanding the drivers of progression of breast ductal carcinoma in situ (DCIS) to invasive breast carcinoma is a key unanswered question in breast cancer with great translational relevance, given the high frequency of DCIS diagnoses in the mammographic screening era and the lack of robust biomarkers. Escaping the host immune response could be critically important, thus we assessed the immune milieu of DCIS and correlated this for the first time with the genomic characteristics of the tumour. We found that, unlike invasive breast cancer, levels of genomic copy number change in DCIS correlate positively with the presence of immune cells. Progression to invasive disease may therefore require copy number driven immunoediting, and suggest that a combination of copy number and immune-cell markers could be evaluated as potential biomarkers of invasive potential. Experimental Design: We quantified tumour associated lymphocytes (TILs) and evaluated PD-L1 protein levels by immunohistochemistry in a cohort of pure DCIS (138 and 79 cases respectively), some of which had copy number (n=55) and mutation data (n=20).
Introduction
It is increasingly recognised that the host immune response to cancer is important in disease progression and response to treatment (1) . The presence of a robust immune response in triple negative and HER2 positive invasive breast carcinoma, as determined by scoring of tumour infiltrating lymphocytes (TILs) on haematoxylin and eosin (H&E) stained sections, is associated with favorable prognosis and improved response to neoadjuvant chemotherapy (reviewed in (2) ) and in the adjuvant setting to docetaxel, trastuzumab and pertuzumab (3) . It has been suggested that the immune response in invasive breast cancer and other tumour types may correlate with mutational load due to the potential for neoantigen formation (4), or alternatively with the specific mutational signature (5) . Higher TILs are consistently seen in triple negative breast cancers, followed by HER2 positive cancers, with high TIL scores observed only rarely in luminal cancers (6) .
The host immune response to tumours has gained prominence following the recent successes of immune checkpoint inhibitor therapies (7, 8) . Immune checkpoint molecules including PD-L1 and CTLA-4 function to induce tolerance to self-antigens and prevent over-activation of the adaptive immune response (7, 9) . PD-L1 can be expressed both on tumor cells and infiltrating immune cells, and may correlate with favorable prognosis and response to immune checkpoint inhibitor therapy in diverse tumor types including non-small cell lung carcinoma, melanoma and urothelial carcinoma (10) (11) (12) (13) (14) . PD-L1 expression in invasive breast carcinomas is most common in tumor cells in triple negative cancers and correlates closely with the extent of the immune infiltrate (15, 16) . imprecise (17). Histopathological factors such as nuclear grade, hormone receptor expression and comedo necrosis, and genomic alterations including copy number changes have been shown to correlate with disease progression (17, 18) . Less is known about the immune response to DCIS and its potential prognostic significance. The concept of cancer immunoediting (19) suggests that tumours progressively develop mechanisms of immune evasion, such as loss of immunogenic antigens or the creation of an immunosuppressive microenvironment (20) . Study of pre-invasive lesions such as DCIS may provide interesting insights into immunoediting in breast carcinoma. In this study, we sought to investigate TILs and PD-L1 expression in DCIS and to correlate these parameters with clinicopathological features and genomic information.
Materials and Methods

DCIS Cohorts
Cases were obtained from the Peter MacCallum Cancer Centre (PMCC), the University of Whole tissue H&E sections were available for a total of 138 cases of pure DCIS without associated invasive breast carcinoma, details of which are available in Supplementary Table   1 . The cases were obtained from PMCC (n=46), UQCCR (n=37) and RMH (n=55 (18, 21) Two tissue microarrays (TMAs) were constructed containing a) two 2 mm cores from 44 PMCC cases, and b) two 0.6 mm cores from 35 UQCCR cases, with 56 cases overlapping with the full section H&E study. Most cases were treated with wide local excision (57/79, 72%) with 24% treated by mastectomy. Radiotherapy was undertaken for 22 patients (28%), and five were treated with hormonal therapy (6%). Follow up data was available for 76 cases (median length 3 years 2 months, range 1 month -20 years 2 months), of which 21 (27.6%) had a recurrence (11 as DCIS, 10 as invasive).
Assessment of tumour infiltrating lymphocytes
TILs were assessed on whole H&E-stained sections containing DCIS. The percentage stromal TILs, defined as the percentage of stromal area covered by mononuclear inflammatory cells, was estimated in the specialized stroma surrounding DCIS-containing ducts (22, 23) . Tumour infiltrating lymphocytes data were obtained from TCGA invasive breast cancer data (n=887 with associated Level 3 Affymetrix SNP6 copy number data) using the "biospecimen_ slide_brca" file, excluding those with 0% tumour and averaging the TILs from cases with more than one slide.
Immunohistochemistry (IHC)
Three micron formalin fixed paraffin embedded tissue sections were stained on the Ventana BenchMark® ULTRA system (Tucson, Arizona, USA) using Ventana PD-L1 (SP263) Rabbit Staining associated with comedo necrosis or biopsy site was excluded.
Statistical and data analysis
Copy number analysis was performed as previously described ( (18) and Pang et al., in press ).
Fraction of the genome altered (FGA) was calculated as the percentage of base pairs with copy number gain or loss. Number of telomeric allelic imbalances (NTAI) was calculated as the count of telomeres (excluding chromosome Y) with a gain or loss.
Statistical analyses were performed in R, including Fisher exact tests, two-sample Wilcoxon rank sum tests, one way analysis of variance (ANOVA) and Cox regression (log-rank test).
All tests were two-sided. Tukey multiple comparison post-tests were performed after ANOVA. Statistical significance was determined as p-values of <0.05.
Results
Analysis of tumour infiltrating lymphocytes with DCIS clinico-pathological parameters
Research.
on October Of the 27 DCIS cases with subsequent recurrence, we were able to obtain ipsilateral recurrence tissue for eight cases (7 DCIS and 1 invasive carcinoma) and to score TILs in these tumours. The level of TILs was not significantly different (paired Mann-Whitney test p=0. 22) but there was a trend for the recurrences to have fewer TILs than the primary tumour (Supplementary Figure 2) . The sole invasive recurrence had a TIL count of 1%, the same as the initial DCIS.
PDL1 tumour cell expression is rare in DCIS
Two TMA cohorts comprising 79 cases (from PMCC and UQCCR) were assessed for tumour (TC) and immune cell (IC) PD-L1 expression along with 20 whole sections from the PMCC cohort ( Figure 2 ). Concordance between whole sections and TMA was 87.5% (14/16): one whole section identified focal TC staining that was absent on the TMA core; another case showed focal IC and TC staining missing from the TMA core. Only 9/79 (11%) of DCIS cases showed any tumour cell (TC) expression of PD-L1, which was predominantly weak and Figure   2C ). In contrast, 20/79 (25%) showed PD-L1 expression in the immune cell (IC) compartment, predominantly staining lymphocytes associated with involved ducts ( Figure   2D ). The majority of cases showing TC expression of PD-L1 also showed IC expression (6/9, 67%). PD-L1 expressing cases in either compartment were significantly more likely to be ER negative (p=0.019, 0.001 for TC and IC respectively) and HER2 positive (p=0.046, 0.002 for TC and IC respectively) ( Table 2 ). Cases with PD-L1 positive TC were more significantly more likely to be high grade (p=0.033), but no significant correlation with grade was seen for IC PD-L1 expression (p=0.19). Comedo necrosis was not associated with PD-L1 expression.
There was no significant association of PD-L1 positive staining with recurrence.
A subset of cases had both TIL and PD-L1 scoring (n=56, 71%). There was a positive correlation between expression of PD-L1 and TILs, with PD-L1 positive cases having a significantly higher mean TIL count for both TC (p=0.03) and IC compartments (p<0.001).
Genetic events and the immune response in DCIS
As the presence of genomic alterations may influence the immunogenicity of DCIS lesions, the presence of TILs was compared with existing genomic information. Copy number data was available for 55 cases across two cohorts ( (18) 
NTAI compared with cases with high levels of TILs (p<0.001, Tukey post-tests for both). In contrast, invasive breast cancer cases from TCGA did not demonstrate a significant association between FGA and TIL levels ( Figure 3 ). Low TIL invasive breast cancer cases had a mean FGA of 24.3 (±15.95), while the mean FGA in high TIL cases was 20.4 (±17.1).
When comparing the percentage of TILs with specific genetic events, there was a significant correlation of high TILs with the presence of a TP53 mutation (p=0.033, Mann-Whitney test, Figure 3 ) and also with ERBB2 amplification (p=0.001). No significant association was seen with PIK3CA or GATA3 mutations. In TCGA invasive breast cancer data, TP53 mutation was also associated with higher levels of TILs (p=0.001).
Twenty cases had both mutation and full section PD-L1 IHC data. The NTAI score was significantly higher in cases with positive IC PD-L1 staining (p=0.046, Figure 3) , and there was also a positive trend for TC PD-L1 staining (p=0.098). There was a non-significant trend of TC PD-L1 positivity with TP53 mutation (p=0.13) whereby 3/5 TC PD-L1 positive cases were TP53 mutant. There was no significant association with FGA, PIK3CA mutation or GATA3 mutation, however, these analyses were limited in power by the small number of cases available.
Discussion
In this study evaluating the immune response to DCIS, we have found a number of significant associations and for the first time correlated the immune microenvironment with genetic features of DCIS. We first assessed TILs on H&E sections, which is a reproducible, quick, and inexpensive method of evaluating the immune infiltrate in tumours (24, 25) and has been validated to show prognostic and predictive significance in invasive breast carcinoma (24) . Using this method, we showed that, as in invasive breast carcinoma, TILs appear to be more prevalent in DCIS that is ER negative. In addition, HER2 positive DCIS show a higher TIL score than HER2 negative DCIS. These findings are in agreement with previous studies of the immune microenvironment of DCIS, in which ER-negative tumours showed a trend towards higher immune infiltrates (23, 26, 27) and HER2 positive tumours were strongly associated with a higher stromal TIL count (23) . Despite significant positive associations with histological features that portend a poor prognosis such as high nuclear grade, comedo necrosis, periductal myxoid stroma, ER negativity and HER2 positivity, no significant association was found in our study between TILs and recurrence. Such a result could suggest a protective role of a robust immune infiltrate in high risk DCIS, however, our study was inadequately powered to draw such a conclusion. Disease recurrence following DCIS can occur after many years, and although the TIL cohort was enriched for cases with recurrence (30/138, 21.7%) and a had a prolonged median follow up of 89 months (range 1-304 months), the lack of association between TILs and recurrence requires further investigation in a large cohort with substantial length of follow up to enable a well-powered multivariate analysis.
One such study also failed to find a correlation between TILs and DCIS recurrence (23) .
However, such analysis is complicated by the likely different implication of TILs in different intrinsic subtypes (28) , the different types of lymphocytes present not distinguishable by H&E staining and the difficulty in getting enough cases to make subgroup analysis sufficiently powerful. In this recent study, even with a starting cohort of almost 1500 DCIS cases, the number of cases with very high TIL infiltrate in the luminal A, luminal B/HER2-and triple negative groups was less than 10 each.
A limitation of the study was the restriction of performing TIL scoring on H&E only, thus information as to the functional status of the immune infiltrate was not obtained and it is Overall, higher numbers of T regs were found in DCIS than in normal breast tissue, with the highest number found in invasive breast carcinoma (29) . Similar findings were reported by Lal et al. (30) . Interestingly, T reg infiltration in pancreatic cancer also appears to increase from normal tissue to pre-invasive lesions to invasive adenocarcinoma (31) . The opposite pattern was found for cytotoxic CD8 + T cells, which decreased with malignant progression (31).
These findings support the concept of a progressively immunosuppressive microenvironment allowing immune evasion and disease progression.
Secondly, we performed PD-L1 IHC in DCIS. In contrast to a previous study (27) , PD-L1 expression by DCIS cells was rare in our cohort. Our use of the Ventana SP263 antibody, which in our hands is the most accurate of the commercially available anti-PD-L1 IHC assays (unpublished data), may explain this difference. However, as previously reported (27) , PD-L1 was predominantly expressed on the immune infiltrate. Immune cell PD-L1 expression in invasive breast carcinoma is more common than tumor cell PD-L1 expression, is associated with high risk histological features such as tumor grade, and is more common in triple negative carcinomas (15, (32) (33) (34) . In our cohort of pure DCIS, we identified associations between immune cell PD-L1 expression and ER negativity, but not with high risk histological features such as high nuclear grade or comedo necrosis.
Research. Polarisation towards an immunosuppressive microenvironment due to ER signalling has been suggested as one possibility to explain elevated TILs in ER-negative carcinomas (35) .
Another is the relationship with genetic aberrations, as in melanoma, since the overall mutational load is much higher in triple-negative than luminal subtype breast carcinomas, with higher potential for neoantigen formation (36) . However, there is no evidence that mutational load directly correlates with TILs or immune signatures within breast cancer subtypes (37, 38) . Mutations in specific oncogenes such as PIK3CA appear not to affect the immune response in invasive breast carcinoma (24) , which is supported by our findings in DCIS where neither PIK3CA not GATA3 mutations were related to TILs. We did observe a strong significant association with TP53 mutation, however this could be confounded by the and invasive cancer are scored for both parameters using the same methods, it suggests several intriguing possibilities. First, that the presence of TILs in the stroma surrounding DCIS could be influenced by the antigens produced by copy number variation, a major driver in breast cancer. Secondly, the change in the immune environment when TILs come into widespread direct contact with the carcinoma cells may lead to immune-editing of the tumour based on copy number or moderation of the immune environment by the tumour. Intriguingly, a recent pan-cancer analysis of TILs and copy number suggested that high levels of aneuploidy are correlated with a low immune gene expression profile (38) . In particular, the CD8+ T cell signature was reduced in invasive breast carcinomas with high aneuploidy. This suggests that the evasion of the immune system could be a key event in the progression of DCIS to invasive breast carcinoma and requires tumour immune-editing driven by copy number change to remove neoantigens. Finally, the combination of low-FGA/low NTAI and low-TILs could indicate a DCIS type that is unlikely to progress to invasive disease, and is therefore seldom observed in invasive cohorts. This possibility would be consistent with our previous observation that higher levels of copy number change are associated with increased likelihood of recurrence after DCIS (18) , but considerably larger cohorts of DCIS are required to test this hypothesis, especially given the multiple interacting variables that will need to be considered (ER status, HER2 status, grade, therapy type etc). The utility of a biomarker panel combining tumour-intrinsic copy number data in combination with tumour-extrinsic immune markers remains to be investigated. 
